Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

DaVita Investigation Dropped by U.S. Justice Department

Oct. 2 (Bloomberg) -- DaVita Inc., a provider of kidney-dialysis services, said the U.S. Justice Department ended an investigation into the company and took no action.

The inquiry, begun by the U.S. attorney in St. Louis in March 2005, covered topics including financial relationships with doctors and joint ventures, the Denver-based company said in a statement today. Prosecutors also looked into the administration and billing of Epogen, a drug for anemia, DaVita said.

DaVita cooperated with the investigation, which ended without the government filing charges, demanding payments or seeking changes in company policies, according to the statement.

DaVita fell 0.2 percent to close at $103.44 yesterday in New York Stock Exchange trading.

Peter Grauer, the chairman of Bloomberg LP, serves on the board of DaVita.

To contact the reporter on this story: Phil Serafino in Paris at

To contact the editors responsible for this story: Anthony Aarons at; Phil Serafino in Paris at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.